Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid

Biochemical Pharmacology

Volumn 65, Issue 11, 2003, Pages 1853-1865

  Zhou, Shufeng ^a,c   Kestell, Philip ^b   Baguley, Bruce C ^b   Paxton, James W ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

CYP; DMXAA; Inhibition; Interindividual variation; UGT

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANTINEOPLASTIC AGENT; CYTOCHROME P450; CYTOCHROME P450 1A2; GLUCURONOSYLTRANSFERASE; ISOPROTEIN; LIVER ENZYME;

ARTICLE; CATALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BINDING; DRUG CLEARANCE; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROLYSIS; LIVER MICROSOME; MOLECULAR BIOLOGY; PHASE 1 CLINICAL TRIAL; PLASMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0038392533     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00189-8     Document Type: Article

References (64)

1. Danesi R., De Braud F., Fogli S., Di Paolo A., Del Tacca M. Pharmacogenetic determinants of anti-cancer drug activity and toxicity. Trends Pharmacol. Sci. 22:2001;420-426.
2. Iyer L., Ratain M.J. Pharmacogenetics and cancer chemotherapy. Eur. J. Cancer. 34:1998;1493-1499.
3. Liefers G-J., Tollenaar R.A.E.M. Cancer genetics and their application to individualised medicine. Eur. J. Cancer. 38:2002;872-879.
4. Innocenti F., Iyer L., Ratain M.J. Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. Drug Metab. Dispos. 29:2001;596-600.
5. Innocenti F., Ratain M.J. Update on pharmacogenetics in cancer chemotherapy. Eur. J. Cancer. 38:2002;639-644.
6. Kroemer H.K., Klotz U. Glucuronidation of drugs: a re-evaluation of the pharmacological significance of the conjugates and modulation factors. Clin. Pharmacokinet. 23:1992;292-310.
7. Meech R., Mackenzie P.I. Structure and function of uridine diphosphate glucuronosyltransferases. Clin. Exp. Pharmacol. Physiol. 24:1997;907-915.
8. Rendic S., Di Carlo F.J. Human cytochrome P450 enzyme: a status report summarizing their reactions, substrates, induction, and inhibitors. Drug Metab. Rev. 29:1997;413-580.
9. Burchell B., Brierley C.H., Monaghan G., Clarke D.J. The structure and function of the UDP-glucuronosyltransferase gene family. Adv. Pharmacol. 42:1998;335-338.
10. Tukey R.H., Strassburg C.P. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol. 40:2000;581-616.
11. Bertz R.J., Granneman G.R. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. 32:1997;210-258.
12. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F.P. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals. J. Pharmacol. Exp. Ther. 270:1994;414-423.
13. Shu Y., Cheng Z.N., Liu Z.Q., Wang L.S., Zhu B., Huang S.L., Ou-Yang D.S., Zhou H.H. Interindividual variations in levels and activities of cytochrome P-450 in liver microsomes of Chinese subjects. Acta Pharmacol. Sinica. 22:2001;283-288.
14. Pelkonen O., Maenpaa J., Taavitsainen P., Rautio A., Raunio H. Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 28:1998;1203-1253.
15. Dresser G.K., Spence J.D., Bailey D.G. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin. Pharmacokinet. 38:2000;41-57.
16. Lin J.H., Lu A.Y. Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu. Rev. Pharmacol. Toxicol. 41:2001;535-567.
17. Jameson M.B., Thomson P.I., Baguley B.C., Evans B.D., Harvey V.J., McCrystal M.R., Kestell P. Phase I pharmacokinetic and pharmacodynamic study of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 19:2000;182a.
18. Ching L-M., Joseph W.R., Crosier K.E., Baguley B.C. Induction of tumour necrosis factor-α messenger RNA in humans and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Cancer Res. 54:1994;870-872.
19. Philpott M., Baguley B.C., Ching L-M. Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother. Pharmacol. 36:1995;143-148.
20. Baguley B.C., Cole G., Thomsen L.L., Li Z. Serotonin involvement in the antitumour and host effects of flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother. Pharmacol. 33:1993;77-81.
21. Baguley B.C., Zhuang L., Kestell P. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects. Oncol. Res. 9:1997;550-560.
22. Thomsen L.L., Ching L-M., Baguley B.C. Evidence for the production of nitric oxide by activated macrophages treated with the antitumor agents flavone-8-acetic acid and xanthenone-4-acetic acid. Cancer Res. 50:1990;6966-6970.
23. Thomsen L.L., Ching L-M., Zhuang L., Gavin J.B., Baguley B.C. Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice. Cancer Res. 51:1991;77-81.
24. Zwi L.J., Baguley B.C., Gavin J.B., Wilson W.R. Correlation between immune and vascular activities of xanthenone acetic acid on tumour agents. Oncol. Res. 6:1994;79-85.
25. Cao Z.H., Baguley B.C., Ching L.M. Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Res. 61:2001;1517-1521.
26. Ching L-M., Baguley B.C. Enhancement of in vitro cytotoxicity of mouse peritoneal exudate cells by flavone acetic acid (NSC 347512). Eur. J. Cancer Clin. Oncol. 24:1988;1521-1525.
27. Ching L.-M., Baguley B.C. Effect of flavone acetic acid (NSC 347,512) on splenic cytotoxic effector cells and their role in tumour necrosis. Eur. J. Cancer Clin. Oncol. 25:1989;821-828.
28. Zhou S.F., Paxton J.W., Tingle M.D., Kestell P., Jameson M.B., Thomson P.I., Baguley B.C. Identification and reactivity of the major metabolite (β-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans. Xenobiotica. 31:2001;277-293.
29. Kestell P., Paxton J.W., Rewcastle G.W., Dunlop I., Baguley B.C. Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit. Cancer Chemother. Pharmacol. 43:1999;323-330.
30. Webster L.K., Ellis A.G., Kestell P., Rewcastle G.W. Metabolism and elimination of 5,6-dimethylxanthenone-4-acetic acid in the isolated perfused rat liver. Drug Metab. Dispos. 23:1995;363-368.
31. Zhou S.F., Paxton J.W., Tingle M.D., Kestell P. Species differences in the metabolism of the novel antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro: implications for prediction of metabolic interactions and toxicity in vivo. Xenobiotica. 32:2002;87-107.
32. Miners J.O., Valente L., Lillywhite K.J., Mackenzie P.I., Burchell B., Baguley B.C., Kestell P. Preclinical prediction of factors influencing the elimination of 5,6-dimethylxanthenone-4-acetic acid, a new anticancer drug. Cancer Res. 57:1997;284-289.
33. Zhou S.F., Paxton J.W., Tingle M.D., Kestell P. Identification of the human liver cytochrome P450 isozyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid. Drug Metab. Dispos. 28:2000;1449-1456.
34. Zhou S.F., Paxton J.W., Kestell P., Tingle M.D. Reversible binding of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and blood cells in various species. J. Pharm. Pharmacol. 53:2001;463-471.
35. Rewcastle G.W., Atwell G.J., Baguley B.C., Calveley S.B., Denny W.A. Potential antitumour agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumour in vivo. J. Med. Chem. 32:1989;793-799.
36. Rewcastle G.W., Kestell P., Baguley B.C., Denny W.A. Light-induced breakdown of flavone acetic acid and xanthenone analogues in solution. J. Natl. Cancer Inst. 82:1990;528-529.
37. Robson R.A., Matthews A.P., Miners J.O., McManus M.E., Meyer U.A., Hall P.D., Birkett D.J. Characterisation of theophylline metabolism by human liver microsomes. Br. J. Clin. Pharmacol. 24:1987;293-300.
38. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Garter F.H., Provenzano M.D., Fujimoto E.K., Goeke N.M., Olson B.J., Klenk D.C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150:1985;76-85.
39. Doumas B.T., Biggs H.G. Determination of serum albumin. Stand. Methods Clin. Chem. 7:1972;175-188.
40. Omura T., Sato R. The carbon monoxide binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 23:1964;2370-2378.
41. Zhou S., Paxton J.W., Tingle M.D., McCall J., Kestell P. Determination of two major metabolites of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in hepatic microsomal incubations by high-performance liquid chromatography with fluorescence detection. J. Chromatogr. B Biomed. Sci. Appl. 734:1999;129-136.
42. Zhou S., Kestell P., Tingle M.D., Paxton J.W. Determination of unbound concentration of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in human plasma by ultrafiltration followed by high-performance liquid chromatography with fluorimetric detection. J. Chromatogr. B Biomed. Sci. Appl. 757:2001;359-363.
43. Laemmli U.K. Cleavage of structure proteins during the assembly of the head bacteriophage 14. Nature. 227:1970;680-685.
44. Yamaoka K., Nakagawa T., Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6:1978;165-167.
45. Bhasker C.R., McKinnon W., Stone A., Lo A.C.T., Kubota T., Ishizaki T., Miners J.O. Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics. 10:2000;679-685.
46. Fisher M.B., Paine M.F., Strelevitz T.J., Wrighton S.A. The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab. Rev. 33:2001;273-297.
47. Fisher M.B., VandenBranden M., Findlay K., Burchell B., Thummel K.E., Hall S.D., Wrighton S.A. Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank. Pharmacogenetics. 10:2000;727-739.
48. Strassburg C.P., Kneip S., Topp J., Obermayer-Straub P., Barut A., Tukey R.H., Manns M.P. Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine. J. Biol. Chem. 275:2000;36164-36171.
49. Congiu M., Mashford M.L., Slavin J.L., Desmond P.V. UDP glucuronosyltransferase mRNA levels in human liver disease. Drug Metab. Dispos. 30:2002;129-134.
50. Pacifici G.M., Evangelisti L., Giuliani L., Metelli R.M., Giordani R. Zidovudine glucuronidation in human liver - interindividual variability. Int. J. Clin. Pharmacol. Ther. 34:1996;329-334.
51. Patel M., Tang B.K., Grant D.M., Kalow W. Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam. Pharmacogenetics. 5:1995;287-297.
52. Welfare M.R., Aitkin M., Bassendine M.F., Daly A.K. Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene: lack of a polymorphism in CYP1A2 in Caucasians. Pharmacogenetics. 9:1999;367-375.
53. Landi MT, Sinha R, Lang NP, Kadlubar FF. Human cytochrome P4501A2. In: Ryder W, editor. Metabolic polymorphisms and susceptibility to cancer, vol. 148. Lyon: IARC Scientific Publications; 1999. p. 173-95.
54. Hammons G.J., Yan-Sanders Y., Jin B., Blann E., Kadlubar F.F., Lyn-Cook B.D. Specific site methylation in the 5′-flanking region of CYP1A2 interindividual differences in human livers. Life Sci. 69:2001;839-845.
55. Zhou S.F., Chin R., Tingle M.D., Kestell P., Paxton J.W. Effects of anti-cancer drugs on the metabolism of the novel anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in human liver microsomes. Br. J. Clin. Pharmacol. 52:2001;129-136.
56. Gill H.J., Tingle M.D., Park B.K. N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450 - implications for inhibition of haemotoxicity. Br. J. Clin. Pharmacol. 40:1995;531-538.
57. Green M.D., King C.D., Mojarrabi B., Mackenzie P.I., Tephly T.R. Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab. Dispos. 26:1998;507-512.
58. Funck-Brentano C., Turgeon J., Woosley R.L., Roden D.M. Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. J. Pharmacol. Exp. Ther. 249:1989;134-142.
59. Sperker B., Murdter T.E., Schick M., Eckhardt K., Bosslet K., Kroemer H.K. Interindividual variability in expression and activity of human beta-glucuronidase in liver and kidney - consequences for drug metabolism. J. Pharmacol. Exp. Ther. 281:1997;914-920.
60. Spahn-Lugguth H., Benet L.Z. Acyl glucuronide revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab. Rev. 24:1992;5-48.
61. Lin J.H., Lu A.Y.H. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol. Rev. 49:1997;403-449.
62. Csaszar A., Abel T. Receptor polymorphisms and diseases. Eur. J. Pharmacol. 414:2001;9-22.
63. Saito S., Kasai Y., Nomoto S., Fujiwara M., Akiyama S., Ito K., Nakao A. Polymorphism of tumor necrosis factor in esophageal, gastric or colorectal carcinoma. Hepatogastroenterology. 48:2001;468-470.
64. Honchel R., Mcdonnell S., Schaid D.J., Thibodeau S.N. Tumor necrosis factor-alpha allelic frequency and chromosome 6 allelic imbalance patients with colorectal cancer. Cancer Res. 56:1996;145-149.